FIGURE 65. Maintenance trials – CDAI scores for trials reporting median scores (results for all patients).

FIGURE 65Maintenance trials – CDAI scores for trials reporting median scores (results for all patients)

Inflix, infliximab.

From: Appendix 10, Results for all included studies irrespective of licence indication

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.